Skip to main content

Drug Safety Update

From:
Medicines and Healthcare products Regulatory Agency
Skip to results
  • Simvastatin: updated advice on drug interactions

    Updated contraindications and maximum dose recommendations when taken with a number of other medicines.

    • Therapeutic area: Cardiovascular disease and lipidology and 1 others
    • Published:
  • Statins: interactions, and updated advice for atorvastatin

    Detailed recommendations for dose restrictions when used with some other drugs as interactions may increase the risk of adverse effects, or reduce the effectiveness of statin treatment.

    • Therapeutic area: Cardiovascular disease and lipidology
    • Published:
  • Letters sent to healthcare professionals in June 2017

    Letters were sent about Arsenic Trioxide (Trisenox), Uptravi▼ (selexipag), DepoCyte (cytarabine), Cinryze▼ (C1 esterase inhibitor [human]), and Clexane (enoxaparin sodium).

    • Therapeutic area: Cancer and 7 others
    • Published:
  • Fibrates: first-line treatment not recommended

    Healthcare professionals should not prescribe them to newly diagnosed patients as first-line treatment, except for those with severe hypertriglyceridaemia or those who cannot take statins.

    • Therapeutic area: Cardiovascular disease and lipidology
    • Published: